2. Metabolic Enzyme/Protease
  3. Creatine Kinase
  4. Cyclocreatine phosphate dilithium

Cyclocreatine phosphate dilithium is a synthetic intracellular energy buffer. Cyclocreatine phosphate dilithium mediates antiproliferative activity in cells with high creatine kinase levels and inhibits solid tumor growth. Cyclocreatine phosphate dilithium maintains adenosine triphosphate (ATP) levels and protects tissues from hypoxia, cellular damage and inflammation during ischemic events. Cyclocreatine phosphate dilithium accumulates in skeletal muscle, reduces muscle phosphocreatine and total creatine levels, and acts both as a bioenergetic/anti-inflammatory agent and an experimental tool for the assessment of ischemic injury. Cyclocreatine phosphate dilithium can be used in studies related to solid tumors, heart failure and ischemia.

For research use only. We do not sell to patients.

Cyclocreatine phosphate dilithium

Cyclocreatine phosphate dilithium Chemical Structure

CAS No. : 63784-08-7

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Cyclocreatine phosphate dilithium Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Cyclocreatine phosphate dilithium is a synthetic intracellular energy buffer. Cyclocreatine phosphate dilithium mediates antiproliferative activity in cells with high creatine kinase levels and inhibits solid tumor growth. Cyclocreatine phosphate dilithium maintains adenosine triphosphate (ATP) levels and protects tissues from hypoxia, cellular damage and inflammation during ischemic events. Cyclocreatine phosphate dilithium accumulates in skeletal muscle, reduces muscle phosphocreatine and total creatine levels, and acts both as a bioenergetic/anti-inflammatory agent and an experimental tool for the assessment of ischemic injury. Cyclocreatine phosphate dilithium can be used in studies related to solid tumors, heart failure and ischemia[1][2][3].

In Vitro

Cyclocreatine phosphate (dilithium) is taken up by and inhibits the growth of high-CK solid tumor cell lines, with antiproliferative specificity and potency similar to cyclocreatine[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cyclocreatine phosphate dilithium Related Antibodies
In Vivo

Cyclocreatine phosphate (0.4-1.2 g/kg/day; intraperitoneal injection; administered daily for 14 consecutive days) dilithium prevents isoproterenol (HY-B0468)-induced heart failure in rats or restores function in functionally impaired hearts[2].
Cyclocreatine phosphate (0.8 g/kg/day; intraperitoneal injection; administered daily for 14 consecutive days) dilithium shows no cardiotoxicity in healthy Wistar rats, with all tested cardiac parameters remaining normal[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wistar (adult male, 6-8 weeks old, 180-220 g; isoproterenol-induced heart failure); Wistar albino (adult male, 170-190 g; isoproterenol-induced heart failure)[2]
Dosage: 0.4 g/kg/day (prophylactic); 0.8 g/kg/day (prophylactic, therapeutic, toxicity control); 1.2 g/kg/day (prophylactic)
Administration: i.p.; daily; 14 days (prophylactic, therapeutic, toxicity control); i.p.; daily; 14 days starting 1 h after second isoproterenol dose (therapeutic)
Result: Prophylactically prevented isoproterenol-induced heart failure in rats.
Resuscitated poorly functioning hearts, with all doses restoring ejection fraction, reducing cardiac biomarkers and remodeling, and maintaining normal physical activity without cardiac toxicity.
Molecular Weight

234.99

Formula

C5H8Li2N3O5P
CAS No.
SMILES

O=C(CN1C(N(P(O[Li])(O[Li])=O)CC1)=N)O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Cyclocreatine phosphate dilithium Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cyclocreatine phosphate dilithium63784-08-7Creatine KinaseCKskeletal muscleWistar ratsischemiahigh-CK solid tumor cell linescreatine kinasesolid tumorcardiac remodelingratsmyocardial ATPisoproterenolInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Cyclocreatine phosphate dilithium
Cat. No.:
HY-148150A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.